tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Vir Biotechnology doses first patient in VIR-5525 trial

Vir Biotechnology (VIR) announced that the first patient has been dosed in the company’s Phase 1 clinical trial evaluating VIR-5525, an investigational dual-masked T-cell engager targeting EGFR. VIR-5525 will be evaluated for the treatment of a variety of EGFR-expressing solid tumors in areas of high unmet need such as non-small cell lung cancer, colorectal cancer, head and neck squamous cell carcinoma and cutaneous squamous cell carcinoma.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1